Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study-Reference-Cited by-同舟云学术

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Published:2024-08 Issue:10452 Volume:404 Page:527-539
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Krämer Alwin,Bochtler Tilmann,Pauli Chantal,Shiu Kai-Keen,Cook Natalie,de Menezes Juliana Janoski,Pazo-Cid Roberto A,Losa Ferran,Robbrecht Debbie GJ,Tomášek Jiří,Arslan Cagatay,Özgüroğlu Mustafa,Stahl Michael,Bigot Frédéric,Kim Sun Young,Naito Yoichi,Italiano Antoine,Chalabi Nasséra,Durán-Pacheco Gonzalo,Michaud Chantal,Scarato Jeremy,Thomas Marlene,Ross Jeffrey S,Moch Holger,Mileshkin Linda

Funder

F Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Reference32 articles.

1. Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non-small-cell lung cancer;Aggarwal;JCO Precis Oncol,2023

2. Trends in the approval of cancer therapies by the FDA in the twenty-first century;Scott;Nat Rev Drug Discov,2023

3. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Krämer;Ann Oncol,2023

4. Cancer of unknown primary—epidemiological trends and relevance of comprehensive genomic profiling;Binder;Cancer Med,2018

5. The currently declining incidence of cancer of unknown primary;Rassy;Cancer Epidemiol,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New clinical trials in CUP and a novel paradigm in cancer classification;Nature Reviews Clinical Oncology;2024-09-11

2. Tumour mutational burden: clinical utility, challenges and emerging improvements;Nature Reviews Clinical Oncology;2024-08-27

3. Whole genome sequencing improves tissue of origin diagnosis and treatment options for cancer of unknown primary;2024-08-10

4. Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management;The Lancet;2024-08

5. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial;The Lancet Oncology;2024-08